Tislelizumab (BGB-A317) for relapsed/refractory extranodal NK/T-cell lymphoma: preliminary efficacy and safety results from a phase 2 study

 POSTER   06/2020

For more information about this resource, please submit a medical information request.

Rating

Rate this resource